[HTML][HTML] Clinical significance of deeper molecular responses with four modalities of tyrosine kinase inhibitors as frontline therapy for chronic myeloid leukemia
L Falchi, HM Kantarjian, A Quintas-Cardama, S O'Brien… - Blood, 2012 - Elsevier
Abstract Abstract 164 Background: The achievement of a major molecular remission (MMR)
after imatinib therapy in pts with chronic myeloid leukemia (CML) in chronic phase (CP) …
after imatinib therapy in pts with chronic myeloid leukemia (CML) in chronic phase (CP) …
The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era
M Breccia, G Alimena - Critical reviews in oncology/hematology, 2011 - Elsevier
Tyrosine kinase inhibitors (TKI) have dramatically changed the management and the
outcome of chronic myeloid leukemia (CML) patients. Imatinib is recognized as gold …
outcome of chronic myeloid leukemia (CML) patients. Imatinib is recognized as gold …
Clinical significance of complete cytogenetic response (CCyR) and major molecular response (MMR) achieved with different treatment modalities used as frontline …
ML Alattar, HM Kantarjian, E Jabbour… - Blood, 2011 - Elsevier
Abstract Abstract 745 FN2 Background: Recent studies have shown that treatment of CML-
CP with second generation tyrosine kinase inhibitors (2G-TKI) dasatinib and nilotinib result …
CP with second generation tyrosine kinase inhibitors (2G-TKI) dasatinib and nilotinib result …
[HTML][HTML] Kinetics of molecular response with different tyrosine kinase inhibitors (TKI) used as frontline therapy in chronic myeloid leukemia-chronic phase (CML CP)
K Naqvi, HM Kantarjian, R Luthra, E Jabbour, S O'Brien… - Blood, 2011 - Elsevier
Abstract 3784 Background: TKI are standard therapy for patients with CML CP. Imatinib was
first established as frontline therapy and more recently dasatinib and nilotinib have shown …
first established as frontline therapy and more recently dasatinib and nilotinib have shown …
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
L Falchi, HM Kantarjian, X Wang… - American journal of …, 2013 - Wiley Online Library
Most patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with
tyrosine kinase inhibitors (TKI) achieve complete cytogenetic response (CCyR). An …
tyrosine kinase inhibitors (TKI) achieve complete cytogenetic response (CCyR). An …
[HTML][HTML] Early molecular and cytogenetic responses predicts for significantly longer event free survival (EFS) and overall survival (OS) in patients (pts) with newly …
Abstract Abstract 70 Introduction: Early responses to TKI are an important predictor of long
term outcome. Several approaches have been used to improve outcomes in CML-CP …
term outcome. Several approaches have been used to improve outcomes in CML-CP …
[HTML][HTML] Assessment of major molecular response (Mmr) and complete cytogenetic response (Ccyr) as surrogate outcomes of survival in chronic myeloid leukemia …
H Kwon, J Park, M Shin, S Shin - Value in Health, 2015 - valueinhealthjournal.com
Objectives This study aims to investigate the association of the major molecular response
(MMR) and complete cytogenetic response (CCyR) as surrogate outcomes with overall …
(MMR) and complete cytogenetic response (CCyR) as surrogate outcomes with overall …
[HTML][HTML] Analysis of long term responses and their impact on outcomes in patients with chronic phase CML treated with four different TKI modalities–analysis of 5 …
P Jain, H Kantarjian, ML Alattar, E Jabbour… - The Lancet …, 2015 - ncbi.nlm.nih.gov
Background Several tyrosine kinase inhibitors (TKI) are available for treatment of patients
with chronic myeloid leukemia in chronic phase (CML-CP). We analyzed long term response …
with chronic myeloid leukemia in chronic phase (CML-CP). We analyzed long term response …
[HTML][HTML] Nilotinib versus high-dose imatinib in early chronic phase CML patients who have suboptimal molecular responses to standard-dose imatinib: updated data …
SY Choi, SE Lee, SH Kim, EJ Jang, J Lee, YJ Oh… - Blood, 2012 - Elsevier
Abstract Abstract 3775 Background. In chronic myeloid leukemia (CML), achievement of
optimal responses by time point has improved long-term outcomes. In contrast, several …
optimal responses by time point has improved long-term outcomes. In contrast, several …
[HTML][HTML] “Duration of deep molecular response” has most impact on the success of cessation of tyrosine kinase inhibitor treatment in chronic myeloid leukemia-results …
S Saussele, J Richter, J Guilhot, H Hjorth-Hansen… - Blood, 2017 - Elsevier
Background: The advent of tyrosine kinase inhibitors (TKI) has decisively improved the
survival of patients with chronic myeloid leukemia (CML). Many patients achieve deep …
survival of patients with chronic myeloid leukemia (CML). Many patients achieve deep …